Severe cytomegalovirus disease with encephalitis after CAR‐T cell therapy: A rare but potentially fatal complication
Élie Cousin, Félicie Belicard, Laure Michel, Charlotte Pronier, Nicolas Lassalle, Thierry Lamy, Roch Houot, Faustine Lhomme
Abstract
Cytomegalovirus (CMV) is a ubiquitous herpes virus that develops lifelong latency following primary infection and can be reactivated following immune suppression. CMV encephalopathy has been described in few reports after hematopoietic stem cell transplantation and in patients with acquired immunodeficiency syndrome. To the best of our knowledge, CMV encephalopathy following CAR-T cells infusion had not been previously reported. Initial CMV viral load and monitoring are crucial in patients with CAR-T cells to allow early intervention with aggressive antiviral treatment without delay if needed.
Topics & Concepts
VirologyComplicationCytomegalovirusEncephalitisMedicineDiseaseViral diseaseHuman cytomegalovirusViral encephalitisVirusHerpesviridaePathologySurgeryCAR-T cell therapy researchCytomegalovirus and herpesvirus researchVirus-based gene therapy research